Research graph
References from Exposure–response relationship of sintilimab in advanced gastric cancer: insights from time-dependent pharmacokinetics and biomarker integration for precision immunotherapy. Local targets link to admitted publications; unresolved targets remain external evidence.
Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors
10.1007/s00262-020-02797-0 · 2021 · External reference
Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy
10.1016/j.ejca.2022.05.021 · 2022 · External reference
Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
10.1186/s40425-016-0177-2 · 2016 · External reference
Model-based characterization of the pharmacokinetics of pembrolizumab: a humanized Anti-PD-1 monoclonal antibody in advanced solid tumors
10.1002/psp4.12139 · 2017 · External reference
Upper gastrointestinal tract IrAEs: a case report about Sintilimab-Induced acute erosive hemorrhagic gastritis
10.3389/fimmu.2022.840916 · 2022 · External reference
Analysis of human leukocyte antigen DR alleles, immune-related adverse events, and survival associated with immune checkpoint inhibitor use among patients with advanced malignant melanoma
10.1001/jamanetworkopen.2022.46400 · 2022 · External reference
DNA polymerase epsilon and delta proofreading suppress discrete mutator and cancer phenotypes in mice
10.1073/pnas.0907147106 · 2009 · External reference
Safety and efficacy of immune checkpoint inhibitors in cancer patients and preexisting autoimmune disease: a systematic review and meta-analysis in Non–small-cell lung cancer
10.1016/j.cllc.2023.05.006 · 2023 · External reference
Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors
10.1002/psp4.12143 · External reference
Exposure-response analysis of nivolumab in patients with previously treated or untreated advanced melanoma
10.1002/jcph.962 · External reference
Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology
10.1111/bcp.13996 · 2019 · External reference
Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: a prospective longitudinal pan-cancer study
10.1002/cam4.4675 · 2022 · External reference
Radiomics, tumor volume, and blood biomarkers for early prediction of pseudoprogression in patients with metastatic melanoma treated with immune checkpoint inhibition
10.1158/1078-0432.ccr-20-0020 · 2020 · External reference
Influence of immunoglobulin isotype on therapeutic antibody function
10.1182/blood-2015-09-625343 · 2016 · External reference
Role of the microbiota in immunity and inflammation
10.1016/j.cell.2014.03.011 · 2014 · External reference
Distinct immune-effector and metabolic profile of CD8(+) T cells in patients with autoimmune polyarthritis induced by therapy with immune checkpoint inhibitors
10.1136/ard-2022-222451 · 2022 · External reference
Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours
10.3389/fonc.2024.1331355 · 2024 · External reference
Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody
10.1186/s40425-016-0139-8 · 2016 · External reference
Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients
10.1038/s41416-018-0074-1 · 2018 · External reference
Interpretation of network-based integration from multi-omics longitudinal data
10.1093/nar/gkab1200 · 2022 · External reference
The current and future of biomarkers of immune related adverse events
10.1016/j.rdc.2024.01.004 · 2024 · External reference
Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors
10.1016/j.xcrm.2022.100868 · 2023 · External reference
Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis
10.1093/rheumatology/key358 · 2019 · External reference
Early variation of FDG-PET radiomics features in NSCLC is related to overall survival - the “delta radiomics” concept
10.1016/s0167-8140(16)30042-1 · 2016 · External reference
Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors
10.1007/s40262-019-00748-2 · 2019 · External reference
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer
10.1093/annonc/mdw174 · 2016 · External reference
Population pharmacokinetic/pharmacodynamic modeling of tumor size dynamics in pembrolizumab-treated advanced melanoma
10.1002/psp4.12140 · 2017 · External reference
Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade
10.1158/2159-8290.cd-15-1545 · 2016 · External reference
TNF in the era of immune checkpoint inhibitors: friend or foe?
10.1038/s41584-021-00584-4 · 2021 · External reference
Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors
10.3389/fimmu.2022.779691 · 2022 · External reference
Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab
10.1080/2162402x.2016.1249559 · 2016 · External reference
Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future
10.1002/cpt.659 · 2017 · External reference
Model-informed precision dosing: background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy
10.1146/annurev-pharmtox-033020-113257 · 2021 · External reference
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
10.1186/s40425-019-0805-8 · 2019 · External reference
Early B cell changes predict autoimmunity following combination immune checkpoint blockade
10.1172/jci96798 · 2018 · External reference
Early pembrolizumab clearance as prognostic biomarker for non-response in patients with advanced non-small cell lung cancer
10.1002/ijc.70052 · 2025 · External reference
Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients
10.1016/j.eururo.2020.04.044 · 2020 · External reference
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
10.1016/s1470-2045(22)00197-8 · 2022 · External reference
Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors
10.18632/oncotarget.23217 · 2017 · External reference
Dynamic testing of stimulative and suppressive biomarkers on peripheral blood cells at early stages of immunotherapy predicts response in advanced cancer patients
2018 · External reference
A tutorial on target-mediated drug disposition (TMDD) models
10.1002/psp4.41 · 2015 · External reference
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
10.1038/ncomms10391 · 2016 · External reference
Using model-based “Learn and Confirm” to reveal the pharmacokinetics-pharmacodynamics relationship of pembrolizumab in the KEYNOTE-001 trial
10.1002/psp4.12132 · 2017 · External reference
Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
10.1038/s41598-019-50574-6 · 2019 · External reference
Peripheral CD8(+) T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma
10.1038/s41591-019-0734-6 · 2020 · External reference
Distinct functional metagenomic markers predict the responsiveness to Anti-PD-1 therapy in Chinese non-small cell lung cancer patients
10.3389/fonc.2022.837525 · 2022 · External reference
Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma
10.1158/1078-0432.ccr-12-3243 · 2013 · External reference
Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma
10.1111/bcp.12323 · 2014 · External reference
Nivolumab exposure-response analyses of efficacy and safety in previously treated squamous or nonsquamous non-small cell lung cancer
10.1158/1078-0432.ccr-16-2842 · 2017 · External reference
Nivolumab
10.1358/dot.2014.50.12.2235103 · 2014 · External reference
Pembrolizumab for the treatment of non-small-cell lung cancer
10.1056/nejmoa1501824 · 2015 · External reference
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
10.1126/science.aan4236 · 2018 · External reference
Antibody drug clearance: an underexplored marker of outcomes with checkpoint inhibitors
10.1158/1078-0432.ccr-23-1683 · 2024 · External reference
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
10.1016/j.ejca.2018.11.009 · 2019 · External reference
BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors
10.1016/j.jaad.2019.08.045 · 2020 · External reference
Replicative DNA polymerase mutations in cancer
10.1016/j.gde.2013.12.005 · 2014 · External reference
Patient-derived tumor spheroid cultures as a promising tool to assist personalized therapeutic decisions in breast cancer
10.21037/tcr-21-1577 · 2022 · External reference
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
10.1038/s41568-024-00705-7 · 2024 · External reference
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
10.1038/nature22079 · 2017 · External reference
PD-1 inhibitor-based adverse events in solid tumors: a retrospective real-world study
10.3389/fphar.2022.974376 · 2022 · External reference
Continuous learning in model-informed precision dosing: a case study in pediatric dosing of vancomycin
10.1002/cpt.2088 · 2021 · External reference
Ancestral diversity in pharmacogenomics affects treatment for hispanic/latine populations with inflammatory bowel disease
10.1016/j.cgh.2024.07.032 · 2025 · External reference
Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis
10.1038/363558a0 · 1993 · External reference
Combined mismatch repair and POLE/POLD1 defects explain unresolved suspected Lynch syndrome cancers
10.1038/ejhg.2015.252 · 2016 · External reference
The terrible triad of checkpoint inhibition: a case report of myasthenia gravis, myocarditis, and myositis induced by cemiplimab in a patient with metastatic cutaneous squamous cell carcinoma
10.1155/2020/5126717 · 2020 · External reference
Utility and impact of quantitative pharmacology on dose selection and clinical development of immuno-oncology therapy
10.1007/s00280-024-04643-x · 2024 · External reference
Sintilimab induced ICIAM in the treatment of advanced HCC: a case report and analysis of research progress
10.3389/fimmu.2022.995121 · 2022 · External reference
Safety profile of monoclonal antibody compared with traditional anticancer drugs: an analysis of Henan Province spontaneous reporting system database
10.3389/fphar.2021.760013 · 2021 · External reference
Predicting and preventing immune checkpoint inhibitor toxicity: targeting cytokines
10.1016/j.it.2021.02.006 · 2021 · External reference
Software tools for model-informed precision dosing: how well do they satisfy the needs?
10.3389/fphar.2020.00620 · 2020 · External reference
Confounding factors in exposure-response analyses and mitigation strategies for monoclonal antibodies in oncology
10.1111/bcp.14662 · 2021 · External reference
The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs)
10.1111/1759-7714.13341 · 2020 · External reference
Clinical pharmacokinetics of therapeutic monoclonal antibodies
10.2165/11531280-000000000-00000 · 2010 · External reference
Immune dysregulation in cancer patients developing immune-related adverse events
10.1038/s41416-018-0155-1 · 2019 · External reference
Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer
10.1073/pnas.1922867117 · 2020 · External reference
Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab
10.1111/cas.13800 · 2018 · External reference
Immune-related adverse events of checkpoint inhibitors and human leukocyte antigen system: a review
10.2147/itt.s548443 · 2025 · External reference
Antibody isotypes for tumor immunotherapy
10.1159/000479240 · 2017 · External reference
Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors
10.1111/cas.14363 · 2020 · External reference
The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study
10.3389/fimmu.2023.1325462 · 2023 · External reference
Sources of inter-individual variability leading to significant changes in anti-PD-1 and anti-PD-L1 efficacy identified in mouse tumor models using a QSP framework
10.3389/fphar.2022.1056365 · 2022 · External reference
Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies
10.1080/07853890.2021.1931956 · 2021 · External reference
Predictive biomarkers for checkpoint inhibitor immune-related adverse events
10.3390/cancers15051629 · 2023 · External reference
A guide to the organ-on-a-chip
10.1038/s43586-022-00118-6 · 2022 · External reference
Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response
10.1007/s10928-017-9528-y · 2017 · External reference
Semimechanistically based modeling of pembrolizumab time-varying clearance using 4 longitudinal covariates in patients with non–small cell lung cancer
10.1016/j.xphs.2018.10.064 · 2019 · External reference
Hypophysitis induced by sintilimab in the treatment of bladder cancer: a case report
10.2174/0118715303257557231002064417 · 2024 · External reference
Circulating cytokines predict immune-related toxicity in melanoma patients receiving Anti-PD-1-Based immunotherapy
10.1158/1078-0432.ccr-18-2795 · 2019 · External reference
Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review
10.1186/s12902-022-01151-y · 2022 · External reference
Preliminary report on the short-term efficacy and safety of SAPO-S1 therapy for locally advanced gastric cancer with a deep learning perspective
10.1080/02648725.2023.2202513 · External reference
Impact of using time-averaged exposure metrics on binary endpoints in exposure-response analyses
10.3389/fphar.2024.1487062 · External reference
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
10.1007/s13238-017-0408-4 · 2018 · External reference
Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis
10.1002/cpt.656 · 2017 · External reference
Identification of HLA-DRB1 association to adalimumab immunogenicity
10.1371/journal.pone.0195325 · 2018 · External reference
One-year mortality in patients with cancer cachexia: association with albumin and total protein
10.2147/cmar.s318728 · External reference
Evolution of delayed resistance to immunotherapy in a melanoma responder
10.1038/s41591-021-01331-8 · External reference
The applicability of the results in the Asian population of ORIENT-11 to a Western population according to the ICH-E5 framework
10.3389/fonc.2022.859892 · 2022 · External reference
Predictive factors of nivolumab-induced hypothyroidism in patients with non-small cell lung cancer
10.21873/invivo.11166 · 2017 · External reference
Myocarditis in patients treated with immune checkpoint inhibitors
10.1016/j.jacc.2018.02.037 · 2018 · External reference
Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study
10.1186/s13045-024-01651-5 · 2024 · External reference
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
10.1016/s1470-2045(20)30445-9 · 2020 · External reference
Time-dependent population PK models of single-agent atezolizumab in patients with cancer
10.1007/s00280-021-04276-4 · 2021 · External reference
FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors
10.1158/1078-0432.ccr-18-4070 · 2019 · External reference
Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma
10.1136/jitc-2024-010059 · 2025 · External reference
Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery
10.1038/s41591-022-01681-x · 2022 · External reference
MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors
10.1172/jci.insight.132334 · 2020 · External reference
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
10.1038/s41571-019-0218-0 · External reference
Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1
10.1038/s41591-022-01698-2 · 2022 · External reference
The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer
10.1016/j.ctrv.2012.08.003 · 2013 · External reference
Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non-small cell lung cancer
10.3389/fimmu.2022.912180 · 2022 · External reference
An integrated multi-omics prediction model for stroke recurrence based on L(net) transformer layer and dynamic weighting mechanism
10.1016/j.compbiomed.2024.108823 · 2024 · External reference
Model-informed precision dosing: state of the art and future perspectives
10.1016/j.addr.2024.115421 · 2024 · External reference
Neoadjuvant immunotherapy: leveraging the immune system to treat early-stage disease
10.1200/edbk_349411 · 2022 · External reference
Immunogenicity of monoclonal antibodies and the potential use of HLA haplotypes to predict vulnerable patients
10.3389/fimmu.2022.885672 · 2022 · External reference
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
10.1016/s0140-6736(18)30533-6 · 2018 · External reference
An uncertainty-aware dynamic decision framework for progressive multi-omics integration in classification tasks
10.1016/j.cmpb.2025.109179 · 2026 · External reference
Simulation-based assessment of the impact of non-adherence on endoxifen target attainment in different tamoxifen dosing strategies
10.3390/ph14020115 · 2021 · External reference
A PK/PD analysis of circulating biomarkers and their relationship to tumor response in atezolizumab-treated non-small cell lung cancer patients
10.1002/cpt.1198 · 2019 · External reference
Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?
10.1186/s40425-019-0799-2 · 2019 · External reference
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors
10.1016/j.medj.2022.12.007 · 2023 · External reference
Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire
10.1158/0008-5472.can-16-2324 · 2017 · External reference
Nivolumab-induced myositis and myocarditis with positive anti-titin antibody and anti-voltage-gated potassium channel Kv1.4 antibody
10.2169/internalmedicine.8772-21 · 2022 · External reference
Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases: early therapeutic drug monitoring of adalimumab
10.1007/s10067-025-07307-0 · 2025 · External reference
Prognostic value of nivolumab clearance in non-small cell lung cancer patients for survival early in treatment
10.1007/s40262-023-01316-5 · 2023 · External reference
Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: translating TNF-α experience to oncology
10.1002/cpt.211 · 2016 · External reference
Integration of multi-omics data using adaptive graph learning and attention mechanism for patient classification and biomarker identification
10.1016/j.compbiomed.2023.107303 · 2023 · External reference
Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer
10.1158/1078-0432.ccr-21-0410 · 2021 · External reference
Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors
10.1634/theoncologist.2018-0563 · 2019 · External reference
Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors
10.1007/s00262-020-02585-w · 2020 · External reference
The emerging therapies are reshaping the first-line treatment for advanced hepatocellular carcinoma: a systematic review and network meta-analysis
10.1177/17562848241237631 · 2024 · External reference
Model-informed precision dosing (MIPD)
10.3390/pharmaceutics14122731 · 2022 · External reference
Modelling of the time-varying pharmacokinetics of therapeutic monoclonal antibodies: a literature review
10.1007/s40262-019-00816-7 · 2020 · External reference
Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study
10.1001/jamaoncol.2017.2411 · 2017 · External reference
Time-dependent clearance can confound exposure-response analysis of therapeutic antibodies: a comprehensive review of the current literature
10.1111/cts.13676 · 2024 · External reference
Sintilimab combined with acetaminophen aggravates liver injury through apoptotic and disturbed bile acid pathways
10.1016/j.tox.2025.154106 · 2025 · External reference
The tumor immune microenvironment: implications for cancer immunotherapy, treatment strategies, and monitoring approaches
10.3389/fimmu.2025.1621812 · 2025 · External reference
Time is money: optimizing the scheduling of nivolumab
10.1200/jco.18.00045 · 2018 · External reference
Pembrolizumab versus chemotherapy for PD-L1-Positive non-small-cell lung cancer
10.1056/nejmoa1606774 · 2016 · External reference
Germinal immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors
10.1007/s10637-019-00845-w · 2020 · External reference
Kikuchi disease: a case report about Sintilimab-induced kikuchi histiocytic necrotizing lymphadenitis and literature review
10.1016/j.heliyon.2024.e30608 · 2024 · External reference
Hypoxic tumor microenvironment: implications for cancer therapy
10.1177/1535370220934038 · 2020 · External reference
A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development
10.1007/s10928-023-09850-2 · 2023 · External reference
Pharmacokinetics of monoclonal antibodies
10.1002/psp4.12224 · 2017 · External reference
Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies
10.1007/s12094-019-02214-8 · 2020 · External reference
Association between specific human leukocyte antigen alleles and development of thyroid immune-related adverse event
10.1080/1750743x.2024.2353539 · 2024 · External reference
HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with crohn’s disease
10.1053/j.gastro.2019.09.041 · 2020 · External reference
Real-time monitoring of drug pharmacokinetics within tumor tissue in live animals
10.1126/sciadv.abk2901 · 2022 · External reference
Microbiota links to immunotherapy toxicity
10.1038/s41568-021-00390-w · 2021 · External reference
Case report: dialysis following sintilimab-induced stage 3 acute kidney injury: mechanism investigation and management strategies
10.3389/fonc.2025.1632740 · 2025 · External reference
Population pharmacokinetic models of anti-PD-1 mAbs in patients with multiple tumor types: a systematic review
10.3389/fimmu.2022.871372 · 2022 · External reference
Immune checkpoint therapy—current perspectives and future directions
10.1016/j.cell.2023.03.006 · 2023 · External reference
Abstract 2233: prediction and comparison of PD-1 receptor occupancy in the tumor after treatment with immune checkpoint inhibitors
10.1158/1538-7445.am2020-2233 · 2020 · External reference
Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma
10.1002/cpt.587 · 2017 · External reference
Sintilimab plus bevacizumab followed by resection in intermediate-stage hepatocellular carcinoma: a phase Ib clinical trial with biomarker analysis
10.1136/bmjonc-2024-000578 · 2024 · External reference
Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities
10.1073/pnas.1908079116 · 2019 · External reference
Safety and efficacy of PD-1/PD-L1 inhibitors in cancer patients with preexisting autoantibodies
10.3389/fimmu.2022.893179 · 2022 · External reference
Predictive value of longitudinal systemic inflammatory markers for pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer
10.21037/tlcr-24-598 · 2024 · External reference
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
10.1186/s40425-015-0081-1 · 2015 · External reference
Checkpoint inhibitor immune-related adverse events: a focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities
10.3389/fimmu.2022.991433 · 2022 · External reference
Profiling preexisting antibodies in patients treated with Anti-PD-1 therapy for advanced non-small cell lung cancer
10.1001/jamaoncol.2018.5860 · 2019 · External reference
Immune biomarkers for checkpoint blockade in solid tumors: transitioning from tissue to peripheral blood monitoring and future integrated strategies
10.3390/cancers17162639 · 2025 · External reference
Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance
10.1158/1078-0432.ccr-18-0415 · 2018 · External reference
Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
10.1186/s12967-018-1467-x · 2018 · External reference
Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy
10.1038/s43018-019-0022-x · 2020 · External reference
Antidrug antibody formation in oncology: clinical relevance and challenges
10.1634/theoncologist.2016-0061 · 2016 · External reference
Reasons for treatment discontinuation and their effect on outcomes of immunotherapy in Southwest Finland: a retrospective, real-world cohort study
10.3390/cancers16040709 · 2024 · External reference
Immunogenicity of pembrolizumab (pembro) in patients (pts) with advanced melanoma (MEL) and non-small cell lung cancer (NSCLC): pooled results from KEYNOTE-001, 002, 006, and 010
10.1200/jco.2016.34.15_suppl.3063 · 2016 · External reference
Quantitative characterization of the exposure-response relationship for cancer immunotherapy: a case study of nivolumab in patients with advanced melanoma
10.1002/psp4.12133 · 2017 · External reference
Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis
10.1001/jamaoncol.2018.3923 · 2018 · External reference
Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit
10.1080/19420862.2019.1654303 · External reference
Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma
10.1186/s40425-019-0819-2 · External reference
Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis
10.1001/jamaoncol.2019.0393 · External reference
A machine-learning approach to identify a prognostic cytokine signature that is associated with nivolumab clearance in patients with advanced melanoma
10.1002/cpt.1724 · 2020 · External reference
The role of cytokines in predicting the response and adverse events related to immune checkpoint inhibitors
10.3389/fimmu.2021.670391 · 2021 · External reference
Efficacy analysis of combining sintilimab with neoadjuvant chemotherapy in treating middle and advanced rectal cancer based on big data
10.1155/2022/8675587 · External reference
Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers
10.3389/fimmu.2022.987568 · External reference
Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: a real-world study
10.1016/j.xcrm.2022.100911 · 2023 · External reference
Case report: a case of sintilimab-induced recurrent diabetic ketoacidosis and thyroid dysfunction in a patient with advanced cervical carcinoma
10.3389/fimmu.2024.1405856 · External reference
Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors
10.1186/s12865-024-00599-y · External reference
SOX plus sintilimab vs P-SOX vs SOX as neoadjuvant therapy in advanced gastric cancer: efficacy and safety
10.4251/wjgo.v17.i8.109646 · 2025 · External reference
Unresolved reference
2017 · External reference
Time-varying clearance and impact of disease state on the pharmacokinetics of avelumab in merkel cell carcinoma and urothelial carcinoma
10.1002/psp4.12406 · 2019 · External reference
Research progress of sintilimab in the treatment of cancer
10.3892/ol.2025.14986 · 2025 · External reference
Sequential severe immune-related adverse events induced by PD-1 inhibitor: a case report and literature review
10.3389/fonc.2024.1391698 · 2024 · External reference
Sintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction: a case report and literature review
10.2217/imt-2023-0325 · 2024 · External reference
The dynamic interplay between the gut microbiota and autoimmune diseases
10.1155/2019/7546047 · 2019 · External reference
LBA53 sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): first results of a randomized, double-blind, phase III study
10.1016/j.annonc.2021.08.2133 · 2021 · External reference
Serum IL-27 predicts the severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study
10.7150/ijms.67028 · 2022 · External reference
Abstract CT078: first-line treatment with sintilimab (sin) vs placebo in combination with chemotherapy (chemo) in patients (pts) with unresectable gastric or gastroesophageal junction (G/GEJ) cancer: final overall survival (OS) results from the randomized, phase III ORIENT-16 trial
10.1158/1538-7445.am2023-ct078 · 2023 · External reference
Development of a lung immune prognostic index-based nomogram model for predicting overall survival and immune-related adverse events in non-small cell lung cancer patients treated with sintilimab
10.3389/fimmu.2025.1569689 · 2025 · External reference
Adverse skin reactions induced by sintilimab in advanced lung squamous carcinoma: a case report and review of the literature
10.21037/atm-22-5925 · 2022 · External reference
Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors
10.1016/j.intimp.2022.109638 · 2023 · External reference
Case report: toxic epidermal necrolysis associated with sintilimab in a patient with relapsed thymic carcinoma
10.3389/fonc.2022.1065137 · 2022 · External reference
Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency
10.1016/j.ejca.2020.02.049 · 2020 · External reference
Impact of fibrinogen-to-albumin ratio on the long-term prognosis of patients with advanced HER2-negative gastric cancer receiving immunochemotherapy
10.4251/wjgo.v17.i6.107980 · 2025 · External reference
Case report: successful immune checkpoint inhibitor rechallenge after sintilimab-induced guillain-barré syndrome
10.3389/fimmu.2025.1546886 · 2025 · External reference
Increased circulating levels of CRP and IL-6 and decreased frequencies of T and B lymphocyte subsets are associated with immune-related adverse events during combination therapy with PD-1 inhibitors for liver cancer
10.3389/fonc.2022.906824 · 2022 · External reference
Sintilimab-induced diabetes mellitus and thyroid dysfunction in patient with gastric adenocarcinoma: a case report and literature review
10.1097/md.0000000000042490 · 2025 · External reference
Model-based population pharmacokinetic analysis of nivolumab in Chinese patients with previously treated advanced solid tumors, including non-small cell lung cancer
10.1002/jcph.1432 · 2019 · External reference
Sintilimab: a promising anti-tumor PD-1 antibody
10.3389/fonc.2020.594558 · 2020 · External reference
A model-based meta-analysis of immune-related adverse events during immune checkpoint inhibitors treatment for NSCLC
10.1002/psp4.12834 · 2022 · External reference
Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors
10.3389/fcimb.2023.1099063 · 2023 · External reference
Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients – a case report and review of the literature
10.1016/j.heliyon.2024.e24380 · 2024 · External reference
Monitoring the plasma concentration of ripretinib and its metabolites in Chinese patients with gastrointestinal stromal tumors in a real-life setting
10.1002/cncr.70149 · 2025 · External reference
Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors
10.1093/annonc/mdx235 · 2017 · External reference
Time-dependent pharmacokinetics of immune checkpoint inhibitors and their implications and considerations for exposure–response analysis
10.1007/s40495-023-00346-8 · 2023 · External reference
Study on the efficacy of brucea javanica oil emulsion combined with sintilimab regulating TGF-β/Smads pathway in gastric cancer patients
10.3969/j.issn.1671-038x.2025.07.10 · 2025 · External reference
A case report: interstitial pneumonia following treatment of gastric cancer with sintilimab in combination with S-1
10.3389/fphar.2025.1508558 · 2025 · External reference
Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring
10.1038/s41591-020-0915-3 · 2020 · External reference
